Neuropathy Pain Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 171 SKU: IRTNTR43322

Neuropathy Pain Treatment Market 2024-2028

The Neuropathy Pain Treatment Market size is estimated to grow by USD 5.84 billion at a CAGR of 10.96% between 2023 and 2028. 

There is a growing focus on the development of drugs for the treatment of diabetic neuropathy pain. Several market players are increasingly focusing on the development of drugs for the treatment of diabetic neuropathy to increase their market presence. In addition, diabetic neuropathy is a nerve disorder caused by diabetes. Moreover,  diabetic neuropathy is associated with high unmet medical needs, such as complications that are characterized by loss of nervous sensation, which can further result in foot ulcers and major amputations. Therefore, such drug developments are positively impacting the market. 

Technavio has segmented the market into  Indication, Distribution Channel, and Geography

  • The indication segment is classified into diabetic neuropathy, chemotherapy-induced neuropathy pain, postherpetic neuralgia, and others
  • The distribution channel segment is classified into retail pharmacies, hospital pharmacies, and online pharmacies
  • The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the size of the Neuropathy Pain Treatment Market During the Forecast Period?

To learn more about this report, Request Free Sample

Neuropathy Pain Treatment Market Segmentation by Indication, Distribution Channel, and Geography Analysis

Indication Analysis

The diabetic neuropathy segment is estimated to witness significant growth during the forecast period. Diabetic neuropathy can be referred to as a nerve disorder associated with diabetes. In addition, due to diabetic neuropathy, axonal damage decreases nerve action potential, thereby inhibiting neuronal signal transmission. Moreover, diabetic neuropathy is characterized by progressive damage to the myelin sheath, which slows down nerve conduction velocity.

Get a glance at the market contribution of various segments Download PDF Sample

The diabetic neuropathy segment was the largest segment and was valued at USD 2.96 billion in 2018. Moreover, about 60%-70% of diabetic patients develop neuropathy, with a considerable number of patients remaining undiagnosed during the initial years of progression. In addition, some of the companies that offer drugs for the treatment of diabetic neuropathy include Eli Lilly, Pfizer, and Assertio Therapeutics. Furthermore,  pain management therapies for diabetic neuropathy are less effective or have undesirable side effects; therefore, the demand for more effective drugs is increasing which is fuelling the growth of this segment. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Distribution Channel Analysis

Retail pharmacies

Retail pharmacists segment sell medicine and medical-related products, as well as other goods such as toiletries, cosmetics, and veterinary products, to the general public and medical practitioners. In addition, retail pharmacies are independent pharmacy, or chain pharmacy, that is licensed as a pharmacy by the state and dispenses medications to the general public at retail prices. Moreover, these pharmacies are typically located across areas for ease of access. In addition, in comparison with wholesale pharmacies, retail pharmacies have a low market share owing to reliability and convenience. Hence, the increasing demand for neuropathy pain treatment therapeutics from retail pharmacies is fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Hospital pharmacies

This segment mainly sells drugs and other pharmaceutical-related products from different pharmaceutical companies and is used for the treatment of either outpatients or inpatients. In addition, the drugs that are found in hospital pharmacies include therapeutic and critical care drugs. Moreover, the primary aim of hospital pharmacies is to procure, store, and sell medications to patients in hospitals. Furthermore, hospital pharmacies have rapidly emerged as the preferred distribution channel for compounded drugs. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominated the global neuropathy pain treatment market with the US being the largest revenue contributor to the market growth. In addition, the growing prevalence of diabetes has led to an increase in the prevalence of diabetic neuropathy. 

Moreover, in 2023, approximately 30.3 million people in the US of all ages have diabetes. Thus, these individuals have a higher risk of developing diabetic neuropathy, a nerve disorder that causes pain. Furthermore, factors such as the increase in the older population, coupled with the established adoption of LYRICA and Cymbalta in new indications and the introduction of new drugs for the treatment of neuropathy pain, will further drive market growth in North America during the forecast period.

COVID Recovery Analysis

In 2020, during the COVID-19 pandemic, the growth of the global neuropathy pain treatment market witnessed a significant slowdown due to the major focus on treating patients with COVID-19, healthcare treatments for other diseases, including neurologic disorders, are reduced in North America. However, in 2021, the initiation of large-scale vaccination drives lifted the lockdown and travel restrictions, which led to the resumption of healthcare facilities and the manufacturing of neuropathy pain drugs. Such factors are expected to drive the market during the forecast period.

Buy Full Report Now

Key Neuropathy Pain Treatment Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories: The company offers neuropathy pain treatment such as the Proclaim XR spinal cord stimulation system, which provides patients with painful diabetic peripheral neuropathy.

  • Alfasigma Spa
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Co.
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • Mallinckrodt Plc
  • Neuracle Lifesciences Pvt. Ltd.
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • VistaGen Therapeutics Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Neuropathy Pain Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Neuropathy Pain Treatment Market Drivers

One of the key factors driving the neuropathy pain treatment market growth is the rising penetration of generic drugs. The presence of generic drugs significantly impacts the market as the price of generic drugs is almost half the price of branded drugs. In addition, with an increase in the number of ANDA approvals, more generic drug manufacturers have entered the market, which is intensifying the competition in the market.

Moreover, the competition among generic drug makers is based on the low prices of generic drugs. For instance, as per the US FDA, with a single generic drugs manufacturer in the market, the average manufacturer price (AMP) for generics is 39% lower than the AMP for branded drugs before the entry of generics into the market. Furthermore, with two competitors, the AMP data shows that the prices of generics are 54% lower than the prices of branded drugs before the entry of generics into the market. Hence, such factors are driving the market growth during the forecast period.

Significant Neuropathy Pain Treatment Market Trends

A key factor shaping the neuropathy pain treatment market growth is the growing focus on emerging economies. The growing focus of research institutes and market players to tap the potential treatments in emerging economies will likely bring substantial growth opportunities. In addition, the increasing incidence of individuals with pain has fueled the demand in regions such as China, India, and Brazil.

Moreover, the research institutes have issued guidelines to address the unmet needs in the treatment of pain. For example, a group of pain specialists from across APAC stated to have tailored guidelines for each region for the treatment of neuropathic pain.  Furthermore, they also started to put greater effort into communicating about neuropathy pain treatments with general physicians which will increase the accessibility of drugs in emerging and low- and middle-income regions of APAC. Hence, such factors drive the market growth during the forecast period.

Major Neuropathy Pain Treatment Market Challenges

High unmet needs in the treatment of neuropathy pain affecting adoption rates are one of the key challenges hindering market growth. The high unmet medical requirements in the diagnosis and treatment of neuropathy pain may negatively impact the growth prospects. In addition, the currently approved therapies for diabetic neuropathy are associated with high systematic toxicity and have failed to eradicate neuropathy completely. Furthermore, neuropathy pain fails to respond adequately to conventional analgesics.

Moreover, the existing treatment for diabetic neuropathy is associated with high systematic toxicity and is not effective in eradicating neuropathy completely. In addition, these drugs are usually associated with side effects such as dizziness, somnolence, nausea, and constipation. As a result, these factors have decreased the levels of patient compliance with diabetic neuropathy drugs. Hence, such factors are hindering the market growth during the forecast period.

Buy Now Full Report

Key Neuropathy Pain Treatment Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Neuropathy Pain Treatment Market Customer Landscape

Segment Overview

The neuropathy pain treatment market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Indication Outlook
    • Diabetic neuropathy
    • Chemotherapy-induced neuropathy pain
    • Postherpetic neuralgia
    • Others
  • Distribution Channel Outlook
    • Retail pharmacies
    • Hospital pharmacies
    • Online pharmacies
  •  Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World
      • Australia
      • Argentina
      • Brazil

Neuropathy Pain Treatment Market Scope

Report Coverage

Details

Page number

171

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 10.96%

Market Growth 2024-2028

USD 5.84 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

10.11

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 33%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Neuracle Lifesciences Pvt. Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., and VistaGen Therapeutics Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Neuropathy Pain Treatment Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the  neuropathy pain treatment market between 2024 and 2028
  • Precise estimation of the neuropathy pain treatment market size and its contribution of the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of neuropathy pain treatment market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global neuropathy pain treatment market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global neuropathy pain treatment market 2018 - 2022 ($ million)
    • 4.2 Indication Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Indication Segment 2018 - 2022 ($ million)
    • 4.3 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Indication

    • 6.1 Market segments
      • Exhibit 30: Chart on Indication - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Indication - Market share 2023-2028 (%)
    • 6.2 Comparison by Indication
      • Exhibit 32: Chart on Comparison by Indication
      • Exhibit 33: Data Table on Comparison by Indication
    • 6.3 Diabetic neuropathy - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Diabetic neuropathy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on Diabetic neuropathy - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on Diabetic neuropathy - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Diabetic neuropathy - Year-over-year growth 2023-2028 (%)
    • 6.4 Chemotherapy-induced neuropathy pain - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Chemotherapy-induced neuropathy pain - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on Chemotherapy-induced neuropathy pain - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on Chemotherapy-induced neuropathy pain - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Chemotherapy-induced neuropathy pain - Year-over-year growth 2023-2028 (%)
    • 6.5 Postherpetic neuralgia - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Postherpetic neuralgia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Data Table on Postherpetic neuralgia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 44: Chart on Postherpetic neuralgia - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Postherpetic neuralgia - Year-over-year growth 2023-2028 (%)
    • 6.6 Others - Market size and forecast 2023-2028
      • Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 6.7 Market opportunity by Indication
      • Exhibit 50: Market opportunity by Indication ($ million)
      • Exhibit 51: Data Table on Market opportunity by Indication ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 54: Chart on Comparison by Distribution Channel
      • Exhibit 55: Data Table on Comparison by Distribution Channel
    • 7.3 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.4 Hospital pharmacies - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 68: Market opportunity by Distribution Channel ($ million)
      • Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 72: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 Canada - Market size and forecast 2023-2028
      • Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.10 China - Market size and forecast 2023-2028
      • Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.11 UK - Market size and forecast 2023-2028
      • Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ million)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 Abbott Laboratories
              • Exhibit 119: Abbott Laboratories - Overview
              • Exhibit 120: Abbott Laboratories - Business segments
              • Exhibit 121: Abbott Laboratories - Key news
              • Exhibit 122: Abbott Laboratories - Key offerings
              • Exhibit 123: Abbott Laboratories - Segment focus
            • 12.4 Astellas Pharma Inc.
              • Exhibit 124: Astellas Pharma Inc. - Overview
              • Exhibit 125: Astellas Pharma Inc. - Product / Service
              • Exhibit 126: Astellas Pharma Inc. - Key news
              • Exhibit 127: Astellas Pharma Inc. - Key offerings
            • 12.5 AstraZeneca Plc
              • Exhibit 128: AstraZeneca Plc - Overview
              • Exhibit 129: AstraZeneca Plc - Product / Service
              • Exhibit 130: AstraZeneca Plc - Key news
              • Exhibit 131: AstraZeneca Plc - Key offerings
            • 12.6 Baxter International Inc.
              • Exhibit 132: Baxter International Inc. - Overview
              • Exhibit 133: Baxter International Inc. - Business segments
              • Exhibit 134: Baxter International Inc. - Key news
              • Exhibit 135: Baxter International Inc. - Key offerings
              • Exhibit 136: Baxter International Inc. - Segment focus
            • 12.7 Biogen Inc.
              • Exhibit 137: Biogen Inc. - Overview
              • Exhibit 138: Biogen Inc. - Product / Service
              • Exhibit 139: Biogen Inc. - Key offerings
            • 12.8 Bristol Myers Squibb Co.
              • Exhibit 140: Bristol Myers Squibb Co. - Overview
              • Exhibit 141: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 142: Bristol Myers Squibb Co. - Key news
              • Exhibit 143: Bristol Myers Squibb Co. - Key offerings
            • 12.9 Daiichi Sankyo Co. Ltd.
              • Exhibit 144: Daiichi Sankyo Co. Ltd. - Overview
              • Exhibit 145: Daiichi Sankyo Co. Ltd. - Product / Service
              • Exhibit 146: Daiichi Sankyo Co. Ltd. - Key news
              • Exhibit 147: Daiichi Sankyo Co. Ltd. - Key offerings
            • 12.10 Dr Reddys Laboratories Ltd.
              • Exhibit 148: Dr Reddys Laboratories Ltd. - Overview
              • Exhibit 149: Dr Reddys Laboratories Ltd. - Business segments
              • Exhibit 150: Dr Reddys Laboratories Ltd. - Key offerings
              • Exhibit 151: Dr Reddys Laboratories Ltd. - Segment focus
            • 12.11 Eli Lilly and Co.
              • Exhibit 152: Eli Lilly and Co. - Overview
              • Exhibit 153: Eli Lilly and Co. - Product / Service
              • Exhibit 154: Eli Lilly and Co. - Key news
              • Exhibit 155: Eli Lilly and Co. - Key offerings
            • 12.12 Endo International Plc
              • Exhibit 156: Endo International Plc - Overview
              • Exhibit 157: Endo International Plc - Business segments
              • Exhibit 158: Endo International Plc - Key news
              • Exhibit 159: Endo International Plc - Key offerings
              • Exhibit 160: Endo International Plc - Segment focus
            • 12.13 Johnson and Johnson
              • Exhibit 161: Johnson and Johnson - Overview
              • Exhibit 162: Johnson and Johnson - Business segments
              • Exhibit 163: Johnson and Johnson - Key news
              • Exhibit 164: Johnson and Johnson - Key offerings
              • Exhibit 165: Johnson and Johnson - Segment focus
            • 12.14 Pfizer Inc.
              • Exhibit 166: Pfizer Inc. - Overview
              • Exhibit 167: Pfizer Inc. - Product / Service
              • Exhibit 168: Pfizer Inc. - Key news
              • Exhibit 169: Pfizer Inc. - Key offerings
            • 12.15 Sanofi
              • Exhibit 170: Sanofi - Overview
              • Exhibit 171: Sanofi - Business segments
              • Exhibit 172: Sanofi - Key news
              • Exhibit 173: Sanofi - Key offerings
              • Exhibit 174: Sanofi - Segment focus
            • 12.16 Sun Pharmaceutical Industries Ltd.
              • Exhibit 175: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 176: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 177: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.17 VistaGen Therapeutics Inc.
              • Exhibit 178: VistaGen Therapeutics Inc. - Overview
              • Exhibit 179: VistaGen Therapeutics Inc. - Product / Service
              • Exhibit 180: VistaGen Therapeutics Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 181: Inclusions checklist
                • Exhibit 182: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 183: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 184: Research methodology
                • Exhibit 185: Validation techniques employed for market sizing
                • Exhibit 186: Information sources
              • 13.5 List of abbreviations
                • Exhibit 187: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              neuropathy pain treatment market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis